1 |
(cdp6038 |
- |
- |
- |
- |
046 1件: 46 💬 |
2 |
2-cda |
Cladribine |
1件: D01370 D01370 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 1件: 13 💬 |
3 |
2-cda, 2-chloro-2'-deoxy-beta-d-adenosine |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
4 |
2-cda, 2-chloro-2'-deoxy-ß-d-adenosine |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
5 |
2-cda, 2-chloro-2?-deoxy-beta-d-adenosine |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
6 |
2-cda, 2-chloro-2?-deoxy-ß-d-adenosine |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
7 |
2-cda, 2-chloro-2’-deoxy-beta-d-adenosine |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
8 |
2-cda, 2-chloro-2’-deoxy-ß-d-adenosine |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
9 |
2-chloro-2'-deoxy-beta-d-adenosine (2-cda) |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
10 |
2-chloro-2'-deoxy-ß-d-adenosine (2-cda) |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
11 |
2-chloro-2'-deoxyadenosine (2-cda) |
Cladribine |
1件: D01370 D01370 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 1件: 13 💬 |
12 |
2-chloro-2’-deoxy-beta-d-adenosine (2-cda) |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
13 |
2-chloro-2’-deoxy-ß-d-adenosine (2-cda) |
Adenosine |
2件: D00045 D00045, D01370 D01370 💬 |
ADORA1 5件: ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 |
Alcoholism 17件: Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
14 |
2-chloro-2’-deoxyadenosine (2-cda) |
Cladribine |
1件: D01370 D01370 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
013 1件: 13 💬 |
15 |
Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase a cdna |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
16 |
Allo-asc-cd |
- |
- |
- |
- |
096 1件: 96 💬 |
17 |
Anti cd3 monoclonal antibody |
- |
- |
- |
- |
097 1件: 97 💬 |
18 |
Anti-cd19-car-t cells |
- |
- |
- |
- |
049 1件: 49 💬 |
19 |
Anti-cd20 b cell depletion with truxima |
- |
- |
- |
- |
049 1件: 49 💬 |
20 |
Anti-cd20 small modular immunopharmaceutical, wye-400087 |
- |
- |
- |
- |
046 1件: 46 💬 |
21 |
Anti-cd25 humanized monoclonal antibody |
- |
- |
- |
- |
013 1件: 13 💬 |
22 |
Anti-cd28dab |
- |
- |
- |
- |
049 3件: 49, 53, 160 💬 |
23 |
Anti-cd3 |
Muromonab |
1件: D05092 D05092 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
096 2件: 96, 97 💬 |
24 |
Anti-cd3 monoclonal antibody |
Muromonab |
1件: D05092 D05092 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
096 2件: 96, 97 💬 |
25 |
Anti-cd40l |
Toralizumab |
1件: D06193 D06193 💬 |
CD40LG 1件: CD40LG 💬 |
Allograft rejection 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, T cell receptor signaling pathway, Toxoplasmosis, Viral myocarditis |
063 1件: 63 💬 |
26 |
Anti-cd40ldab |
- |
- |
- |
- |
063 1件: 63 💬 |
27 |
Anti-cd45 |
- |
- |
- |
- |
060 3件: 60, 65, 285 💬 |
28 |
Anti-cd52 monoclonal antibody |
- |
- |
- |
- |
013 1件: 13 💬 |
29 |
Ap-cd/ld |
- |
- |
- |
- |
006 1件: 6 💬 |
30 |
Autologous cd34+ cell transduced with g2scid vector |
- |
- |
- |
- |
065 1件: 65 💬 |
31 |
Autologous cd34+ cells transduced ex-vivo with the pcclchimgp91/vsvg lentiviral vector |
- |
- |
- |
- |
065 1件: 65 💬 |
32 |
Autologous cd34+ cells transduced with a lentiviral vector containing the human sgsh gene |
- |
- |
- |
- |
019 1件: 19 💬 |
33 |
Autologous cd34+ cells transduced with a lentiviral vector encoding the arsa cdna |
- |
- |
- |
- |
019 1件: 19 💬 |
34 |
Autologous cd34+ cells transduced with lenti-d vector encoding abcd1 cdna |
- |
- |
- |
- |
020 1件: 20 💬 |
35 |
Autologous cd34+ cells transduced with the lentiviral vector containing the human wiskott aldrich sy |
- |
- |
- |
- |
065 1件: 65 💬 |
36 |
Autologous cd34+ enriched cell fraction that contains cd34+ cells transduced with lentiviral vector that encodes for the human wiskott aldrich syndrome (was) cdna sequence |
- |
- |
- |
- |
065 1件: 65 💬 |
37 |
Autologous cd34+ hscs transduced ex vivo with efs lentiviral vector encoding for the human ada gene |
- |
- |
- |
- |
065 1件: 65 💬 |
38 |
Autologous cd34+cells transduced with the w1.6_hwasp_wpre (vsvg) lentiviral vector |
- |
- |
- |
- |
065 1件: 65 💬 |
39 |
Autologous cd34-selected peripheral blood stem cells transplant |
- |
- |
- |
- |
096 1件: 96 💬 |
40 |
Autologous cd4+t cells stimulated and expanded ex vivo by a mog peptide modified by the introduction of a thioreductase motif into the flanking residues of the t cell epitope |
- |
- |
- |
- |
013 1件: 13 💬 |
41 |
Autologous haematopoietic stem cells transduced with lentiviral vector lenti-d encoding the human abcd1 cdna |
- |
- |
- |
- |
020 1件: 20 💬 |
42 |
Autologous stemcell transplantation with cd (cluster of differentiation) 34 selected stem cells |
- |
- |
- |
- |
051 1件: 51 💬 |
43 |
Bardoxolone methyl, cddo-me, cddo-methyl ester, nsc 713200, chemical name: oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester |
Bardoxolone |
2件: D09584 D09584, D09585 D09585 💬 |
- |
- |
086 1件: 86 💬 |
44 |
Biologic: ic14 (monoclonal antibody against human cd14) |
- |
- |
- |
- |
002 1件: 2 💬 |
45 |
Blinded cdca 250 mg tid |
Chenodeoxycholic acid |
1件: D00163 D00163 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
263 1件: 263 💬 |
46 |
Bt061 (cd4 monoclonal antibody) |
- |
- |
- |
- |
046 1件: 46 💬 |
47 |
Cd |
- |
- |
- |
- |
006 6件: 6 , 46, 51, 96, 97, 265 💬 |
48 |
Cd-4 guided therapy interruption |
- |
- |
- |
- |
265 1件: 265 💬 |
49 |
Cd-ld cr |
- |
- |
- |
- |
006 1件: 6 💬 |
50 |
Cd-ld ir |
- |
- |
- |
- |
006 1件: 6 💬 |
51 |
Cd19-directed humanised afucosylated monoclonal antibody |
- |
- |
- |
- |
011 1件: 11 💬 |
52 |
Cd3/cd19 depleted leukocytes |
- |
- |
- |
- |
284 1件: 284 💬 |
53 |
Cd3/cd19 neg allogeneic bmt |
- |
- |
- |
- |
065 1件: 65 💬 |
54 |
Cd3/cd19 negative allogeneic hematopoietic stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
55 |
Cd3/cd19 negative hematopoietic stem cells |
- |
- |
- |
- |
085 1件: 85 💬 |
56 |
Cd34 selected autologous hematopoietic cells |
- |
- |
- |
- |
051 1件: 51 💬 |
57 |
Cd34 stem cell selection therapy |
- |
- |
- |
- |
060 3件: 60, 65, 284 💬 |
58 |
Cd34+ |
- |
- |
- |
- |
065 1件: 65 💬 |
59 |
Cd34+ bone marrow stem cells intravitreal |
- |
- |
- |
- |
090 1件: 90 💬 |
60 |
Cd34+ cells |
- |
- |
- |
- |
285 1件: 285 💬 |
61 |
Cd34+ cells transduced with ada retrovir |
- |
- |
- |
- |
065 1件: 65 💬 |
62 |
Cd34+ enriched, t cell depleted donor stem cell product |
- |
- |
- |
- |
326 1件: 326 💬 |
63 |
Cd34+ hscs transduced with the lentivirus vector, vsv-g pseudotyped cl20-4i-ef1a-h?c-opt |
- |
- |
- |
- |
065 1件: 65 💬 |
64 |
Cd34+ selected cells |
- |
- |
- |
- |
285 1件: 285 💬 |
65 |
Cd34+cells |
- |
- |
- |
- |
065 2件: 65, 285 💬 |
66 |
Cd34+sc |
- |
- |
- |
- |
051 1件: 51 💬 |
67 |
Cd45ra depleted leukocytes |
- |
- |
- |
- |
284 1件: 284 💬 |
68 |
Cd45ra-depleted dli |
- |
- |
- |
- |
060 2件: 60, 65 💬 |
69 |
Cd62l- tem |
- |
- |
- |
- |
060 1件: 60 💬 |
70 |
Cdca |
Chenodeoxycholic acid |
1件: D00163 D00163 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
263 1件: 263 💬 |
71 |
Cdca weight-based dose tid |
Chenodeoxycholic acid |
1件: D00163 D00163 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
263 1件: 263 💬 |
72 |
Cdmard |
- |
- |
- |
- |
046 1件: 46 💬 |
73 |
Cdnf |
- |
- |
- |
- |
006 1件: 6 💬 |
74 |
Cdp |
- |
- |
- |
- |
046 1件: 46 💬 |
75 |
Cdp 6038 sc |
- |
- |
- |
- |
046 1件: 46 💬 |
76 |
Cdp3194 |
- |
- |
- |
- |
049 1件: 49 💬 |
77 |
Cdp323 |
CDP323 |
- |
- |
- |
013 1件: 13 💬 |
78 |
Cdp6038 |
- |
- |
- |
- |
046 2件: 46, 96 💬 |
79 |
Cdp7657 |
- |
- |
- |
- |
049 1件: 49 💬 |
80 |
Cdp870 |
- |
- |
- |
- |
046 3件: 46, 96, 271 💬 |
81 |
Cdp870 100mg |
- |
- |
- |
- |
046 1件: 46 💬 |
82 |
Cdp870 200mg |
- |
- |
- |
- |
046 1件: 46 💬 |
83 |
Cdp870 400mg |
- |
- |
- |
- |
046 1件: 46 💬 |
84 |
Cdp870 fab'-peg |
- |
- |
- |
- |
046 1件: 46 💬 |
85 |
Cdx |
- |
- |
- |
- |
222 3件: 222, 223, 240 💬 |
86 |
Cdx 6114 |
- |
- |
- |
- |
240 1件: 240 💬 |
87 |
Cdx-1135 |
- |
- |
- |
- |
222 2件: 222, 223 💬 |
88 |
Cdz173 |
- |
- |
- |
- |
053 2件: 53, 65 💬 |
89 |
Cellule cd34+ autologhe trasdotte con idua lv codificante per il cdna dell'alfa-l-iduronidasi |
- |
- |
- |
- |
019 1件: 19 💬 |
90 |
Certolizumab pegol (cdp870) |
Certolizumab pegol |
1件: D03441 D03441 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 2件: 46, 96 💬 |
91 |
Certolizumab pegol (cdp870, czp) |
Certolizumab pegol |
1件: D03441 D03441 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
096 1件: 96 💬 |
92 |
Certolizumab pegol (cdp870, tradename cimzia) |
Certolizumab pegol |
1件: D03441 D03441 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
93 |
Certolizumab pegol (cdp870, tradename cimzia)(prefilled syringes at the dose of 200mg) |
Certolizumab pegol |
1件: D03441 D03441 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
046 1件: 46 💬 |
94 |
Chimeric human/mouse anti-cd-20 monoclonal antibody |
- |
- |
- |
- |
046 1件: 46 💬 |
95 |
Chx a-dtpa anti-cd66 antibody |
Pentetic acid |
1件: D05422 D05422 💬 |
- |
- |
028 1件: 28 💬 |
96 |
Chx-a-dtpa-anti-cd66 |
Pentetic acid |
1件: D05422 D05422 💬 |
- |
- |
028 1件: 28 💬 |
97 |
Combination of a single dose anti-cd20 antibody and bortezomib |
Bortezomib |
1件: D03150 D03150 💬 |
PSMB5 1件: PSMB5 💬 |
Alzheimer disease 8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia |
061 1件: 61 💬 |
98 |
Cryopreserved autologous cd34+ cells transduced with a lentiviral vector containing human sgsh gene |
- |
- |
- |
- |
019 1件: 19 💬 |
99 |
Cryopreserved efs-ada lv transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
100 |
Cryopreserved g2scid lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
101 |
Cytolytic cd4+ t cells |
- |
- |
- |
- |
013 1件: 13 💬 |
102 |
Cytoreductive regimen followed by a cd34+e- selected allogeneic stem cell transplant |
- |
- |
- |
- |
062 1件: 62 💬 |
103 |
D-methylphenidate |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
104 |
Daclizumab (anti-cd25 humanized monoclonal antibody) |
Daclizumab |
1件: D03639 D03639 💬 |
IL2RA 1件: IL2RA 💬 |
Cytokine-cytokine receptor interaction 11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
013 1件: 13 💬 |
105 |
Depletion in cd45ra graft donor |
- |
- |
- |
- |
065 1件: 65 💬 |
106 |
Device: cell processing for tcrabeta+/cd19+ depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
107 |
Device: cell processing for tcraß+/cd19+ depletion |
- |
- |
- |
- |
065 1件: 65 💬 |
108 |
Device: clinimacs® cd34 reagent system cell sorter device |
- |
- |
- |
- |
065 1件: 65 💬 |
109 |
Device: miltenyi cd34 reagent system |
- |
- |
- |
- |
060 1件: 60 💬 |
110 |
Diltiazem |
Diltiazem |
3件: D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 3件: 51, 58, 86 💬 |
111 |
Diltiazem gel 2% |
Diltiazem |
3件: D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
112 |
Diltiazem hydrochloride |
Diltiazem |
3件: D00616 D00616, D03830 D03830, D07845 D07845 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
113 |
Duodopa ld/cd 20/5 mg/ml |
- |
- |
- |
- |
006 1件: 6 💬 |
114 |
Ef1as-ada lentiviral vector gene modified autologous cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
115 |
Ef1as-ada lentiviral vector transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
116 |
Engineered humanized monoclonal anti-human cd19 antibody. |
- |
- |
- |
- |
046 1件: 46 💬 |
117 |
Engineered humanized monoclonal anti-human cd19 antibody. lot numbers: 1-fin-1588 (9.6mg/ml) |
- |
- |
- |
- |
046 1件: 46 💬 |
118 |
Er cd-ld |
- |
- |
- |
- |
006 1件: 6 💬 |
119 |
Ex vivo culture and transduction of the patient's autologous cd34+ hsc with lentivirus vector vsv-g pseudotyped cl20- 4i-ef1a-hyc-opt vector |
- |
- |
- |
- |
065 1件: 65 💬 |
120 |
Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length lamb3 cdna. |
- |
- |
- |
- |
036 1件: 36 💬 |
121 |
Fc- and cdr-modified humanised monoclonal antibody against c5 |
- |
- |
- |
- |
011 3件: 11, 62, 109 💬 |
122 |
G1xcgd transduced cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
123 |
Gene-transduced autologous cd34+ stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
124 |
Genetic: infusion of autologous cryopreserved efs-ada lv cd34+ cells (otl-101) |
- |
- |
- |
- |
065 1件: 65 💬 |
125 |
Genetic: infusion of autologous efs-ada lv cd34+ (otl-101) |
- |
- |
- |
- |
065 1件: 65 💬 |
126 |
Genetic: infusion of autologous efs-ada lv cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
127 |
Gsk2018682 cd2 capsule |
- |
- |
- |
- |
013 1件: 13 💬 |
128 |
Gsk2018682 cd3 micronised tablet |
- |
- |
- |
- |
013 1件: 13 💬 |
129 |
Gsk2018682 cd3 non-micronised tablet |
- |
- |
- |
- |
013 1件: 13 💬 |
130 |
Gsk2018682 cd3 non-micronised tablet in fed state |
- |
- |
- |
- |
013 1件: 13 💬 |
131 |
Human monoclonal antibody directed against cd20 on b-cells |
- |
- |
- |
- |
046 1件: 46 💬 |
132 |
Humanised anti-cd 20 antibody |
- |
- |
- |
- |
046 1件: 46 💬 |
133 |
Humanised anti-cd4 igg1 monoclonal |
- |
- |
- |
- |
046 1件: 46 💬 |
134 |
Humanized recombinant igg4 monoclonal antibody against cd-127 |
- |
- |
- |
- |
097 1件: 97 💬 |
135 |
Humax-cd20 |
Ofatumumab |
1件: D09314 D09314 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
013 2件: 13, 46 💬 |
136 |
Humax-cd38 |
- |
- |
- |
- |
028 2件: 28, 63 💬 |
137 |
Humax-cd4 |
- |
- |
- |
- |
046 1件: 46 💬 |
138 |
Indium 111-radiolabelled anti-cd66 |
Indium |
- |
- |
- |
028 1件: 28 💬 |
139 |
Indium 111 labelled anti-cd66 |
Indium |
- |
- |
- |
028 1件: 28 💬 |
140 |
Inebilizumab |
Inebilizumab |
1件: D11757 D11757 💬 |
CD19 1件: CD19 💬 |
B cell receptor signaling pathway 5件: B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency |
011 3件: 11, 13, 300 💬 |
141 |
Ipx203 er cd-ld |
- |
- |
- |
- |
006 1件: 6 💬 |
142 |
Ir cd-ld |
- |
- |
- |
- |
006 1件: 6 💬 |
143 |
Ir cd-ld (carbidopa-levodopa) tablets |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
144 |
Ir ld / cd |
- |
- |
- |
- |
006 1件: 6 💬 |
145 |
Ir ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
146 |
Ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
147 |
Lentiviral vector transduced cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
148 |
Levodopa/carbidopa (ld/cd) |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
149 |
Methylphenidate |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 7件: 6 , 13, 34, 84, 113, 179, 206 💬 |
150 |
Methylphenidate (mpd) |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 1件: 6 💬 |
151 |
Methylphenidate (overencapsulated) |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
152 |
Methylphenidate 10mg tablets |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
084 1件: 84 💬 |
153 |
Methylphenidate hydrochloride |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
006 2件: 6 , 13 💬 |
154 |
Methylphenidate modified release |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
155 |
Methylphenidate modified release 20 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
156 |
Methylphenidate modified release 30 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
157 |
Methylphenidate modified release 40 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
158 |
Methylphenidate, fluoxetin, risperidone |
Fluoxetine |
5件: D00326 D00326, D00426 D00426, D00823 D00823, D01296 D01296, D04999 D04999 💬 |
DRD2 5件: DRD2, HTR2A, SLC6A2, SLC6A3, SLC6A4 💬 |
Alcoholism 14件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Rap1 signaling pathway, Serotonergic synapse, Synaptic vesicle cycle, cAMP signaling pathway |
179 2件: 179, 206 💬 |
159 |
Muromonab |
Muromonab |
1件: D05092 D05092 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
060 1件: 60 💬 |
160 |
Muromonab-cd3 |
Muromonab |
1件: D05092 D05092 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
060 1件: 60 💬 |
161 |
Ni-0401 (anti-cd3 mab) |
Muromonab |
1件: D05092 D05092 💬 |
CD3D 3件: CD3D, CD3E, CD3G 💬 |
Chagas disease 11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation |
096 1件: 96 💬 |
162 |
Ono-2160/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
163 |
Open-label cdca 250 mg tid |
Chenodeoxycholic acid |
1件: D00163 D00163 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
263 1件: 263 💬 |
164 |
Other: cd lfd |
- |
- |
- |
- |
096 1件: 96 💬 |
165 |
Other: cd-treat diet |
- |
- |
- |
- |
096 1件: 96 💬 |
166 |
Other: crohn's disease treatment-with-eating diet (cd-treat diet) |
- |
- |
- |
- |
096 1件: 96 💬 |
167 |
Other: diet-cd |
- |
- |
- |
- |
096 1件: 96 💬 |
168 |
Phagocyte oxidase subunit transduced cd34 hematopoietic stem cells |
- |
- |
- |
- |
065 1件: 65 💬 |
169 |
Plerixafor mobilization of autologous cd117 stem cells |
Plerixafor |
1件: D08971 D08971 💬 |
CXCR4 1件: CXCR4 💬 |
Axon guidance 12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
299 1件: 299 💬 |
170 |
Procedure: autologous cd34+hpc transplantation (hsct) |
- |
- |
- |
- |
049 1件: 49 💬 |
171 |
Procedure: cd3-depleted hematopoietic cell transplantation |
- |
- |
- |
- |
060 1件: 60 💬 |
172 |
Procedure: cd34 selected haploidentical pbsct |
- |
- |
- |
- |
285 1件: 285 💬 |
173 |
Procedure: cd34+ peripheral blood stem cell reinfusion |
- |
- |
- |
- |
049 1件: 49 💬 |
174 |
Procedure: cd3±cd19 depleted hematopoietic stem cell transplantation |
- |
- |
- |
- |
060 1件: 60 💬 |
175 |
Procedure: repair of cdh w/alloderm |
- |
- |
- |
- |
294 1件: 294 💬 |
176 |
Procedure: repair of cdh w/sis gold |
Gold |
- |
- |
- |
294 1件: 294 💬 |
177 |
Rag1 lv cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
178 |
Recombinant adeno-associated virus 2/6 vector encoding the cdna for human alpha galactosidase a |
- |
- |
- |
- |
019 1件: 19 💬 |
179 |
Rescue medication cdca 250 mg tid |
Chenodeoxycholic acid |
1件: D00163 D00163 💬 |
NR1H4 1件: NR1H4 💬 |
Bile secretion 1件: Bile secretion |
263 1件: 263 💬 |
180 |
Retroviral sf71-gp91phox transduced cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
181 |
Rituximab (anti-cd20) |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
053 1件: 53 💬 |
182 |
Routine treatment of cd |
- |
- |
- |
- |
096 1件: 96 💬 |
183 |
Semi continuous intra-oral administration of ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
184 |
Standard ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
185 |
Suspension of autologous cd34+cells transduced with the g1xcgd viral vector |
- |
- |
- |
- |
065 1件: 65 💬 |
186 |
T-cell depleted & cd34+select/w/stemcell enriched product |
- |
- |
- |
- |
065 1件: 65 💬 |
187 |
Tl011, anti cd20, for the treatment of rheumatoid arthritis |
- |
- |
- |
- |
046 1件: 46 💬 |
188 |
Transduced cd34+ cells |
- |
- |
- |
- |
285 1件: 285 💬 |
189 |
Transduced patient cd34+ cells |
- |
- |
- |
- |
065 1件: 65 💬 |
190 |
Yttrium-90 radiolabelled anti-cd66 antibody |
Yttrium Y-90 |
- |
- |
- |
028 1件: 28 💬 |
191 |
Yttrium90 radiolabelled anticd66 |
- |
- |
- |
- |
028 1件: 28 💬 |